{"id":"W4206445899","doi":"10.1056/nejmoa1901118","title":"Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1932,"is_retracted":false,"has_abstract":true,"ca_institutions":"LMC Diabetes & Endocrinology (Canada); Ted Rogers Centre for Heart Research","funders":"Novo Nordisk; Steno Diabetes Center Copenhagen","keywords":"Semaglutide; Type 2 diabetes; Medicine; Diabetes mellitus; Internal medicine; Cardiology; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006867429810484486,"score_gpt":0.2157929557860977,"score_spread":0.2089255259756132,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}